Multicenter, Randomized, Double-blind Placebo Controlled Trial of Bezafibrate for the Treatment of Primary Biliary Cirrhosis in Patients With Incomplete Response to Ursodesoxycholic Acid Therapy.
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- Percentage of patients with complete biochemical response.
研究概览
简要总结
Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disease that eventually leads to end-stage liver failure and death unless liver transplantation (LT) is performed. Ursodeoxycholic acid (UDCA) administered orally at the daily dose of 13-15 mg/kg is currently the only drug approved for the treatment of PBC. UDCA consistently improves biochemical liver tests, prolongs survival without LT, and delays histological progression as well as the occurrence of portal hypertension. However, a significant proportion (40%) of patients treated with UDCA shows an incomplete biochemical response and remains at high risk of death or LT. The development of new treatments in combination with UDCA is therefore needed. Several candidates exist among which is Bezafibrate. Bezafibrate belongs to the fibrates' pharmacological class, which has been developed 4 decades ago for the treatment of mixed hyperlipidaemia. Bezafibrate is cheap, widely available and well tolerated. There is now a substantial body of circumstantial evidence supporting that fibrates, and Bezafibrate in particular, are well tolerated and can improve biochemical liver tests in patients with PBC with incomplete response to UDCA. However, despite several positive successful pilot studies, there are still no phase 3 randomized placebo-controlled trials of fibrates for the treatment of PBC. The purpose of this protocol is therefore to conduct such a trial in a selected population of patients with PBC based on an incomplete biochemical response after 6 months of UDCA therapy.
详细描述
This is a multi-center, randomized (treatment will be assigned by chance), placebo-controlled (an inactive substance will be compared with the test drug to see whether the drug has a real effect), parallel-group (two or more groups of patients will receive different treatments) study that will assess the efficacy and safety of bezafibrate in patients with primary biliary cirrhosis (PBC) who had an inadequate biochemical response to ursodeoxycholic acid, as defined by the Paris II criteria. Bezafibrate 400 mg or placebo will be daily administered in combination with ursodeoxycholic acid (UDCA) 13-15 mg/kg/d for 24 months. Patient safety will be monitored. Primary end-point will be the percentage of patients with a complete normalization of the following biochemical tests: alkaline phosphatase, aminotransferases, total bilirubin, serum albumin, and prothrombin index. Secondary endpoints will include the percentage of drug-related adverse events, survival rates without liver transplantation or liver decompensation, time course of non-invasive liver fibrosis measurements (Fibroscan, serum hyaluronic acid), time course of liver histological parameters (fibrosis stage, necro-inflammatory grade, ductopenia) assessed on percutaneous biopsy specimens, time course of endoscopic, ultrasound, and biochemical features of portal hypertension, time course of pruritus and of quality of life using validated scales.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age > 18
- •Patient with PBC defined by 2 in 3 of the following criteria Positive antimitochondrial antibody type M
- •Abnormal serum alkaline phosphatases (ALP > 1,5N) and aminotransferase (AST or ALT > 1N) activities.
- •Histological hepatic injuries consistent with PBC from biopsy specimens of at least 10 mm.
- •Patient treated with UDCA at the dose of 13 to 15 mg/kg/d (consistent to the AMM)
- •Patients showing an incomplete biochemical response to UDCA as defined by : ALP > 1,5N or AST > 1,5N or total bilirubin >17 µmol/l (with conjugated bilirubin > 8 µmol/l) after ≥ 3 months of UDCA at the dose of 13 - 15 mg/kg/day.
排除标准
- •Unsigned consent.
- •Patient with no social insurance or having medical assistant of state
- •Ascites or gastrointestinal bleeding (or history of these)
- •Serum total bilirubinemia > 50 μmols/L (3 mg/dl) (sample < 3 months)
- •Serum albuminemia < 35 g/l (sample < 3 months)
- •Prothrombin index < 70% (sample < 3 months)
- •Platelet count < 100000/mm3 (sample < 3 months)
- •Treatment with corticosteroids, immunosuppressive agents, fibrates (or other PPAR-agonists) or statin in the last 3 months
- •Any comorbidity susceptible to cause a hepatic impairment (HBV, HCV, or HIV seropositivity; excessive alcohol consumption; hemochromatosis, Wilson's disease, α1 antitrypsin deficiency; celiac disease; uncontrolled dysthyroidism; autoimmune hepatitis, inflammatory colitis)
- •Any severe comorbidity decreasing life expectancy
- •Intolerance or hypersensitivity to fibrates, to one of these components or other fibrates in general
- •Known photosensitivity reaction to fibrates
- •Pregnancy or desire of pregnancy
- •Breast-feeding
- •Renal failure (clearance of creatinine < 60 ml/mn)
- •Patient with congenital galactosemia, syndrome of glucose malabsorption, lactase deficiency due to the presence of lactose in tablets of bezafibrate 400 mg
研究组 & 干预措施
Bezafibrate
400 mg/Day
干预措施: Bezafibrate (Drug)
Placebo
1 tablet/ day
干预措施: placebo (Drug)
结局指标
主要结局
Percentage of patients with complete biochemical response.
时间窗: 24 months
The normalisation of hepatic biochemical tests (aminotransferases (AST, ALT), Alkaline Phosphatase, blood Albumin, blood bilirubin and prothrombin index).
次要结局
- Percentage of patients having biological or clinical adverse reaction.(24 months)
- Evolution of the portal hypertension markers.(24 months)
- Percentage of patients having complete biochemical response.(12 months)
- Evolution of the biological markers of the hepatic function or being in the usual prognostic scores (Mayo, Child, MELD).(24 months)
- Assessment of the fatigue and the quality of life.(24 months)
- Evolution of the pruritus.(24 months)
- Evolution of liver fibrosis surrogate markers.(24 months)
- Histological evolution: Histopathological examination of biological sample before enrolment and at the end of the study.(24 months)
- Survival without transplantation and hepatic impairment.(24 months)